News Headline Summary
Summer Street says FDA will not review Sarepta's (SRPT) DMD drug
Reaction details:
- Co. shares are unmoved in immediate reaction to the news; trades USD 30.39 (+0.96%) last,
Print
14:35, 05 Mar 2013 -
US Equities
- Source:
B4THESTREET.COM
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
-
Real-time audio coverage from 0630 to 2130 London time
-
Teams of analysts covering equities, fixed income, FX and energy markets
-
Real-time scrolling news service
-
Daily and weekly pre-market research and calendars
-
Intra-day market update videos
-
Daily technical analysis